Tumor Cells Interleukin-22 Expression Associates with Elevated Tumor-Associated Macrophages Infiltrating and Poor Prognosis in Patients with Breast Cancer
机构：[1]Fourth Hospital of Hebei Medical University, Shijiazhuang, China.河北医科大学第四医院[2]Department of General Surgery,Affiliated Hospital of Hebei University,Baoding,China.河北大学附属医院重点学科普通外科[3]Department of Internal Medicine, First Hospital of Xingtai, Xingtai, China.
Interleukin-22 (IL-22) is identified as a tumor-promoting factor in certain cancers, which was secreted by tumor infiltrated lymphocytes. However, the role of IL-22 in breast cancer remains conflicting. In this study, we assessed the expression of IL-22, IL-22 receptor 1 (IL-22R1), CD4, CD8, FOXP3, and CD68 in breast cancer by immunohistochemistry. IL-22 expression was exhibited in 105 (69.1%) cases in tumor cells (tIL-22), whereas only 24 (15.8%) samples displayed IL-22 expression in stromal cells. Multivariate analysis showed that tIL-22 expression was a poor prognostic factor for overall survival (OS) (p = 0.04). Meanwhile, IL-22R1 was predominantly presented in tumor cells (84.9%), which was associated with tIL-22 expression. The CD68-positive tumor-associated macrophages (TAMs) displayed the highest infiltration rate (50.7%) compared with CD4(-), CD8(-), and FOXP3-positive cells. Kaplan-Meier analysis confirmed patients with high TAM infiltration displayed significantly worse relapse-free survival (RFS) compared with low TAMs group (p = 0.017). TAM infiltration was also positively associated with tIL-22 and IL-22R1 expression. Furthermore, tIL-22 expression together with high TAM infiltration displayed the worst prognosis outcomes both in OS (p = 0.039) and RFS (p = 0.008). Instead of lymphocytes, our data indicated that tumor cells express IL-22 in breast cancer that is associated with IL-22R1, high TAM infiltrating, and poor prognosis.
基金：
Hebei Province Department of Science and Technology Research [162777249, 17277747D]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区核医学4 区药学4 区肿瘤学
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区肿瘤学4 区药学4 区核医学
JCR分区：
出版当年[2021]版：
Q2PHARMACOLOGY & PHARMACYQ2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3MEDICINE, RESEARCH & EXPERIMENTALQ3ONCOLOGY
最新[2023]版：
Q2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3MEDICINE, RESEARCH & EXPERIMENTALQ3ONCOLOGYQ3PHARMACOLOGY & PHARMACY
第一作者机构：[1]Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
共同第一作者：
通讯作者：
通讯机构：[1]Fourth Hospital of Hebei Medical University, Shijiazhuang, China.[3]Department of Internal Medicine, First Hospital of Xingtai, Xingtai, China.[*1]Fourth Hospital of Hebei Medical University, No.12, Jiankang Road, Shijiazhuang 050019, China[*2]First Hospital of Xingtai, No. 376, Shunde Road, Xingtai 054000, China
推荐引用方式(GB/T 7714)：
Zhao Jidong,Liu Hongzhang,Zhang Xiangmei,et al.Tumor Cells Interleukin-22 Expression Associates with Elevated Tumor-Associated Macrophages Infiltrating and Poor Prognosis in Patients with Breast Cancer[J].CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS.2021,36(2):160-166.doi:10.1089/cbr.2020.3794.
APA：
Zhao, Jidong,Liu, Hongzhang,Zhang, Xiangmei,Zhang, Wenqing,Liu, Li...&Zhao, Liyan.(2021).Tumor Cells Interleukin-22 Expression Associates with Elevated Tumor-Associated Macrophages Infiltrating and Poor Prognosis in Patients with Breast Cancer.CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,36,(2)
MLA：
Zhao, Jidong,et al."Tumor Cells Interleukin-22 Expression Associates with Elevated Tumor-Associated Macrophages Infiltrating and Poor Prognosis in Patients with Breast Cancer".CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 36..2(2021):160-166
